Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Goodwill (2016 - 2023)

Coherus Oncology's Goodwill history spans 10 years, with the latest figure at $943000.0 for Q4 2023.

  • For Q4 2023, Goodwill changed 0.0% year-over-year to $943000.0; the TTM value through Dec 2023 reached $943000.0, changed 0.0%, while the annual FY2023 figure was $943000.0, 0.0% changed from the prior year.
  • Goodwill for Q4 2023 was $943000.0 at Coherus Oncology, roughly flat from $943000.0 in the prior quarter.
  • Across five years, Goodwill topped out at $943000.0 in Q1 2019 and bottomed at $943000.0 in Q1 2019.
  • The 5-year median for Goodwill is $943000.0 (2019), against an average of $943000.0.
  • The largest YoY upside for Goodwill was 0.0% in 2019 against a maximum downside of 0.0% in 2019.
  • A 5-year view of Goodwill shows it stood at $943000.0 in 2019, then changed by 0.0% to $943000.0 in 2020, then changed by 0.0% to $943000.0 in 2021, then changed by 0.0% to $943000.0 in 2022, then changed by 0.0% to $943000.0 in 2023.
  • Per Business Quant, the three most recent readings for CHRS's Goodwill are $943000.0 (Q4 2023), $943000.0 (Q4 2022), and $943000.0 (Q4 2021).